Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 147

Sort by

Sort Order Select

Journal Articles

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Blood blood.2024026186.

https://doi.org/10.1182/blood.2024026186

Published: 2024

Includes: Supplemental data

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Niek G. Van Der Maas, Dimitri Breems, Clara Klerk, Thomas Pabst, Patrycja Gradowska, Bart J. Biemond, Jurgen Kuball, Janine Van Elssen, Otto Visser, Marie-Christiane Vekemans, Carlos Graux, Johan Maertens, H. Berna Beverloo, Peter J. M. Valk, Gert J. Ossenkoppele, Bob Lowenberg, Geert A. Huls, Jan J. Cornelissen, Jurjen Versluis

Blood (2023) 142 (Supplement 1): 724.

https://doi.org/10.1182/blood-2023-180812

Published: 2023

Journal Articles

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Blood (2023) 141 (21): 2657–2661.

https://doi.org/10.1182/blood.2022019160

Published: 2023

Includes: Supplemental data

Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Blood (2022) 140 (Supplement 1): 9125–9127.

https://doi.org/10.1182/blood-2022-157753

Published: 2022

Journal Articles

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Niek Van Der Maas, Kazem Nasserinejad, Thomas Pabst, Johan A. Maertens, Dimitri A. Breems, Markus G Manz, Jacqueline Cloos, Gert J. Ossenkoppele, Yngvar Floisand, Patrycja Gradowska, Bob Lowenberg, Gerwin A. Huls, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen, Jurjen Versluis

Blood (2022) 140 (Supplement 1): 127–129.

https://doi.org/10.1182/blood-2022-158137

Published: 2022

Journal Articles

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjørn Tore Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J.W.M. Janssen, Gunnar Juliusson, Johan A. Maertens, Markus G Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter JM Valk, Bob Lowenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2022) 140 (Supplement 1): 2027–2029.

https://doi.org/10.1182/blood-2022-157009

Published: 2022

Journal Articles

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Blood (2022) 139 (15): 2347–2354.

https://doi.org/10.1182/blood.2021014472

Published: 2022

Includes: Supplemental data

Journal Articles

The predictive value of a positive phase 2 ASH abstract for peer-reviewed publication and progression to phase 3

David G. J. Cucchi, Tobias B. Polak, Gert J. Ossenkoppele, Jacob M. Rowe, Elihu H. Estey

Blood (2022) 139 (12): 1920–1923.

https://doi.org/10.1182/blood.2021013988

Published: 2022

Includes: Supplemental data

Journal Articles

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood (2021) 138 (26): 2753–2767.

https://doi.org/10.1182/blood.2021013626

Published: 2021

Includes: Supplemental data

Journal Articles

Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of "Positive" Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 - 2015

David Cucchi, Tobias Polak, Gert J. Ossenkoppele, Jacob M. Rowe, Elihu H. Estey

Blood (2021) 138 (Supplement 1): 4040.

https://doi.org/10.1182/blood-2021-149102

Published: 2021

Journal Articles

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 4041.

https://doi.org/10.1182/blood-2021-149521

Published: 2021

Journal Articles

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Tommaso Matteuzzi, Daniele Dall'Olio, Eric Sträng, Alessandra Merlotti, Javier Martinez Elicegui, Axel Benner, Maral Saadati, Julia Krzykalla, Caroline A. Heckman, Ana Heredia Casanoves, Jurjen Versluis, María Abáigar, Alberto Hernandez-Sanchez, Laura Jamilis, Peter JM Valk, Klaus H. Metzeler, Rosa Ayala, Joaquin Martinez Lopez, Herve Dombret, Pau Montesinos, Jorge Sierra, Claude Preudomme, Frederick Damm, Ken I Mills, Raúl Azibeiro Melchor, Jiří Mayer, Christian Thiede, Maria Teresa Voso, Sergio Amadori, Guillermo Sanz, Frederico Calado, Konstanze Döhner, Verena I Gaidzik, Michael Heuser, Torsten Haferlach, Marta Sobas, Amin T. Turki, Dirk Reinhardt, Rubén Villoria Medina, Michel van Speybroeck, Renate Schulze-Rath, Jesús M Hernández Rivas, Brian J.P Huntly, Hartmut Döhner, Gert J. Ossenkoppele, Castellani Gastone, Lars Bullinger

Blood (2021) 138 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2021-152215

Published: 2021

Journal Articles

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Blood (2021) 138 (Supplement 1): 1303.

https://doi.org/10.1182/blood-2021-148129

Published: 2021

Journal Articles

Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance

Blood (2021) 138 (Supplement 1): 5031.

https://doi.org/10.1182/blood-2021-145002

Published: 2021

Journal Articles

Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation

Blood (2021) 138 (Supplement 1): 1276.

https://doi.org/10.1182/blood-2021-146507

Published: 2021

Journal Articles

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Blood (2021) 138 (Supplement 1): 608.

https://doi.org/10.1182/blood-2021-150766

Published: 2021

Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Blood (2021) 137 (13): 1792–1803.

https://doi.org/10.1182/blood.2020007233

Published: 2021

Includes: Supplemental data

Journal Articles

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

Diana Hanekamp, Lok Lam Ngai, Jeroen J. W. M. Janssen, Arjan van de Loosdrecht, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2021) 137 (12): 1694–1697.

https://doi.org/10.1182/blood.2020007150

Published: 2021

Includes: Supplemental data

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

NARROW

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

The predictive value of a positive phase 2 ASH abstract for peer-reviewed publication and progression to phase 3

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of "Positive" Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 - 2015

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance

Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only